Evaluation of the diagnostic value of alpha‐<scp>l</scp>‐fucosidase, alpha‐fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma

Zhang, Shiyan; Lin, Biding; Li, Bu-Ren

doi:10.1016/j.fob.2015.03.010

Cited by 39 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various biomarkers, including α-fetoprotein (AFP) (13), des-γ-ca rboxy prothrombin (14) and α-l-fucosidase (15), have been identified over the past three decades. However, accurate indicators for the prognosis of HCC are limited.…”

Section: Introductionmentioning

confidence: 99%

High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma

Shen

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. The present study aimed to illustrate the association of the expression of ubiquitin-conjugating enzyme E2A (UBE2A) with the clinicopathological parameters and prognosis in hepatocellular carcinoma (HCC). The expression levels of UBE2A mRNA and protein in a total of 276 HCC tissues and six liver cell lines was detected by fluorescent quantitative polymerase chain reaction, western blotting and immunohistochemistry. Statistical analysis was also performed to assess the association of the expression of UBE2A with the clinicopathological parameters and prognosis by the GraphPad Prism and SPSS version 21.0 software. UBE2A mRNA and protein were highly expressed in HCC tissues compared with those in the adjacent normal tissue. Immunohistochemical analysis revealed that UBE2A protein was more strongly stained in the 276 paraffin-embedded HCC tissues as compared with the 63 adjacent normal tissue. Statistical analysis also demonstrated that UBE2A expression was significantly associated with histological differentiation, TNM stage and vascular invasion of HCC (P<0.05). Notably, HCC patients with a high expression of UBE2A had a shorter survival time as compared with those with a low expression of UBE2A. There results suggested that UBE2A may be involved in the pathogenesis of HCC and may serve as an important prognostic marker.Further exploration of the involvement of UBE2A in HCC development may provide novel therapeutic targets. IntroductionHepatocellular carcinoma (HCC) is the third leading cause of cancer-associated mortality worldwide and the fifth most common cancer type (1). HCC is a global health burden and its prevalence varies worldwide (2). The incidence rate is reported to be higher in Asia (>20 cases/100,000 individuals) in comparison with that in North America and Europe (<5 cases/100,000 individuals) (3). The prognosis of HCC is poor, as evident by the fact that the number of annual mortality cases (~600,000) is almost equal to the number of new cases diagnosed annually (4). The median rate for 1-year survival is 80% (range, 63-97%), for 3-year survival is 70% (range, 34-78%) and for 5-year survival is 50% (range, 17-69%) (5). Surgery remains the most important treatment strategy for patients with HCC. The 5-year survival rate of patients with early HCC subsequent to resection treatment reaches 50%, although these patients exhibit a high recurrence rate (6,7). Despite advances in the diagnosis (8) and treatment (9) of HCC, the prognosis of this disease remains poor (10). Therefore, further clarification of the mechanisms underlying its development is important (11,12).At present, the prognosis of HCC is predicted based on imaging findings and biomarkers. Various biomarkers, including α-fetoprotein (AFP) (13), des-γ-ca rboxy prothrombin (14) and α-l-fucosidase (15), have been identified over the past three decades. However, accurate indicators for the prognosis of HCC are limited. Consequently, there is an urgency to develop a novel biomarker for the prognosis of HCC.The ubiquitin system serves a ...

show abstract

Section: Introductionmentioning

confidence: 99%

High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma

Shen

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Pediatric subjects ranging from 2.5 to 10 years and were ≤18 years old, were included in the study only after signed informed consent of both their related parents or tutors was given. Fucosidase diagnosis was performed according to the previously reported methods . SS in children was diagnosed with the concurrent or alternative presence of bilateral parotid glands associated with dryness of mouth and/or eyes and with at least 1 of these tests (antinuclear antibodies, anti‐double‐stranded DNA, anti‐SSA, anti‐SSB) positive at ≥1:80 …”

Section: Methodsmentioning

confidence: 99%

“…Fucosidase diagnosis was performed according to the previously reported methods. 1,20 SS in children was diagnosed with the concurrent or alternative presence of bilateral parotid glands associated with dryness of mouth and/or eyes and with at least 1 of these tests (antinuclear antibodies, anti-double-stranded DNA, anti-SSA, anti-SSB) positive at ≥1:80. 21…”

Section: Subjectsmentioning

confidence: 99%

“…Human α‐fucosidase (EC 3.2.1.51) is a glycosidase able to hydrolyze O‐ and S‐glycosyl compounds, which has received major attention in recent years as a serological marker in some forms of cancer such as hepatocellular carcinoma . The enzyme is particularly important in a rare form of pathology, known as fucosidosis, which is a severe glycoprotein lysosomal storage disorder, included in the group of oligosaccharides or glycoproteins .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma α‐L‐fucosidase‐1 in patients with Sjögren's syndrome and other rheumatic disorders

et al. 2019

View full text Add to dashboard Cite

Background Human α‐fucosidase (EC 3.2.1.51) is a hydrolase the importance of which has been increasing in the latest years. However, data about its plasma level in children with autoimmune disorders, particularly Sjögren's syndrome (SS), are lacking. In this study, the plasma activity of L‐α‐fucosidase‐1 (α‐L‐FUCA‐1) was assayed in hospitalized children and adults and its association with SS and other rheumatic disorders further evaluated. Methods In total 73 Hungarian hospitalized patients, 32 children (2.5‐10 years) and 41 adults (32‐68 years), were enrolled in the study and underwent plasma assay of α‐L‐FUCA1 activity. Linear regression, Durbin‐Watson (DW), and Pearson tests were evaluated to investigate the relationship between α‐L‐FUCA‐1 plasma levels and autoimmune manifestations. Results α‐L‐FUCA‐1 correlated with SS both in children (2‐sided t test, P = 0.0023) and in adults (2‐sided t test, P = 0.00035). Linear regressions showed that in other rheumatic disorders, α‐L‐FUCA1 did not show any differential distribution related to the particular pathology (r = 0.2042, P = 0.1531, DW test = 2.2139 positive), while this trend was radically opposite for patients with SS (r = 0.1462, P = 0.0032, DW test = 1.3664, negative). Conclusions Alterations in plasma level of α‐L‐FUCA‐1 were significantly associated with SS. This preliminary result should encourage further research on α‐L‐FUCA‐1 as a possible differential serological marker of SS.

show abstract

“…При ГЦК концентрация ТК-1 (ДУ 1,92 пмоль/л) до лече-ния была повышена, однако ROC-анализ показал лучшие значения AUC для α-фетопротеина (0,832), чем для ТК-1 (0,773) [53].…”

Section: тк-1 при солидных опухоляхunclassified

The Thymidine Kinase-1(tk-1) as a Potential Tumor Marker: Serum Levels in Serum of Patients With Solid and System Malignance Neoplasms

Сергеева¹,

Парилова²,

Маршутина³

et al. 2017

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

1 Московский научно-исследовательский онкологический институт им. П.А. Герцена -филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России, 125284, Россия, Москва, 2-й Боткинский проезд, 3; 2 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, 117997, Россия, Москва, ул. Островитянова, 1 РЕЗЮМЕ В обзоре обобщены результаты исследований уровней и/или активности в сыворотке крови метаболического маркера пролиферирующих клеток тимидинкиназы-1 (ТК-1) у больных лимфопролиферативными заболева-ниями (ЛПЗ) и солидными злокачественными новообразованиями (ЗНО).Сопоставление данных литературы в ряде случаев было затруднено из-за использования авторами принци-пиально разных методов выявления активности или концентрации ТК-1, даже несмотря на наличие относи-тельно высокой (но не абсолютной) корреляции между этими показателями (не более 0,8).Многие клинико-лабораторные исследования свидетельствуют о корреляции уровней и/или активности ТК-1 с клиническими стадиями разных видов ЛПЗ и солидных ЗНО и могут служить прогностическим фактором общей и безрецидивной выживаемости больных. При солидных ЗНО показано, что активность ТК-1 адекватно отражает пролиферативный статус опухолей.При сопоставлении динамики ТК-1 в процессе химиотерапии с ее клинической эффективностью разные авто-ры получили принципиально различающиеся результаты: в ряде случаев снижение маркера было ассоции-ровано с эффективностью лечения, а в части публикаций показано, что при клинически значимых эффектах лечения наблюдается повышение маркера после первых курсов химиотерапии.Вся совокупность полученных к настоящему времени данных свидетельствует об актуальности дальнейших разработок алгоритма использования ТК-1 в онкологической практике. КЛЮЧЕВЫЕ СЛОВА:тимидинкиназа-1 (ТК-1), лимфопролиферативные заболевания (ЛПЗ), солидные злокачественные новообразования, опухолеассоциированный маркер

show abstract

Evaluation of the diagnostic value of alpha‐l‐fucosidase, alpha‐fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma

Abstract: HighlightsThymidine kinase 1 (TK1) is a tumor marker for the diagnosis of hepatocellular carcinoma (HCC).Alpha-fetoprotein (AFP) was not detected in 25% of the HCC patients in our study.The combined analysis of AFP, TKI and alpha-l-fucosidase could improve the sensitivity of HCC diagnosis.

Cited by 39 publications

References 23 publications

High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma

High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma

Plasma α‐L‐fucosidase‐1 in patients with Sjögren's syndrome and other rheumatic disorders

The Thymidine Kinase-1(tk-1) as a Potential Tumor Marker: Serum Levels in Serum of Patients With Solid and System Malignance Neoplasms

Contact Info

Product

Resources

About